WE ARE ENDECE
ENDECE, LLC is a privately held biopharmaceutical company focused on discovering and developing new drug therapies to stop or reverse disease progression by controlling key cellular pathways. These therapies exert their control over these pathways by targeting receptors within cell nuclei that regulate certain genes.
Our scientists invented compounds with potential benefit associated with novel mechanisms of action for treating multiple sclerosis (MS) and other neurological diseases. In addition to MS, we focus on diseases whose treatment options are limited or non-existent, whose causes may not be well understood and whose clinical development paths are still undefined.
ENDECE was founded in 2006 and is headquartered in Mequon, Wisconsin.
ENDECE to Present Data on NDC-1308, a Small Molecule with Remyelinating Activity for Treatment of Secondary Progressive Multiple Sclerosis
ENDECE will present “NDC-1308, a Small Molecule with Remyelinating Activity for Treatment of Secondary Progressive Multiple Sclerosis,” during two sessions of the American Academy of Neurology…read more
Endece Neural will be presenting at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) in National Harbor, Maryland.read more